Upgrade to SI Premium - Free Trial

Acadia Pharmaceuticals (ACAD) PT Lowered to $26 at RBC Capital

August 7, 2024 6:24 AM
RBC Capital analyst Gregory Renza lowered the price target on Acadia Pharmaceuticals (NASDAQ: ACAD) to $26.00 (from $29.00) while maintaining ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Analyst PT Change

Next Articles